Last reviewed · How we verify
Solu-Cortef
Solu-Cortef (hydrocortisone sodium succinate) is a rapid-acting corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Solu-Cortef (hydrocortisone sodium succinate) is a rapid-acting corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Acute adrenal insufficiency, Severe allergic reactions and anaphylaxis, Acute inflammation and shock.
At a glance
| Generic name | Solu-Cortef |
|---|---|
| Also known as | hydrocortisone, Hydrocortisone |
| Sponsor | Haukeland University Hospital |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Endocrinology, Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
Hydrocortisone is a synthetic glucocorticoid that mimics the body's natural cortisol. It binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene expression, thereby suppressing pro-inflammatory cytokine production, reducing immune cell activation, and decreasing vascular permeability. The sodium succinate salt formulation allows for rapid intravenous or intramuscular administration, making it suitable for acute inflammatory and allergic emergencies.
Approved indications
- Acute adrenal insufficiency
- Severe allergic reactions and anaphylaxis
- Acute inflammation and shock
- Cerebral edema
- Status asthmaticus
Common side effects
- Hyperglycemia
- Hypokalemia
- Hypertension
- Insomnia
- Mood changes (euphoria, irritability)
- Increased infection risk
- Gastrointestinal upset
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (PHASE1)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (PHASE3)
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |